UNCOVERED: Crispr therapeutics | History Defined

The Outlook of CRISPR Therapeutics Stock Does Not Look Strong After Its CFO Resigns

The valuation of CRSP stock is high, and its pipeline is not advanced.

Barchart · Oct 23

Anthropic Just Made a CRISPR-Like Discovery. What It Actually Means for CRSP Stock Investors.

Anthropic’s AI-driven discovery of a new CRISPR-like enzyme system has pressured gene-editing stocks, but the technology remains at a very early stage, while CRISPR Therapeutics already has an approved therapy and multiple clinical programs.

Barchart · Sep 30

One Infusion Held LDL Cholesterol 52 Percent Lower for a Full Year, in a Trial of Fifteen People

A CRISPR therapy cut LDL cholesterol 52.5% and triglycerides 47.8% a full year after one infusion, in a company-funded trial of 15 patients.

Medical Daily · Aug 31

Studies test whether gene-editing can fix high cholesterol. For now, take your medicine

Scientists are testing an entirely new way to fight heart disease: whether gene editing might offer a one-time fix for high cholesterol

The Independent UK · Feb 11

This Leading Gene-Editing Stock Could Be Going Private. Should You Buy Its Shares First?

CRISPR Therapeutics is the subject of strong buyout speculation after earning FDA approval for a breakthrough gene-editing therapy.

Barchart · Nov 19, 2025

The Best Biotech ETFs to Buy

Biotech ETFs offer investors exposure to the most innovative and growth-oriented industry within the traditionally defensive healthcare sector.

Kiplinger · Oct 2, 2025

CRISPR Stock Surges in Recent Weeks: What's Going On?

CRISPR Therapeutics AG (NASDAQ:CRSP) is trending Thursday, up more than 45% over the past month. Here’s a look at what’s driving the move.

Benzinga · Jul 10, 2025

2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025

Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space.

MarketBeat · Jan 7, 2025

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.

Benzinga · Nov 27, 2024

Markets Today: Stock Index Futures Climb on Dovish PPI Surprise

Morning Markets June S&P 500 futures (ESM2 3) this morning are up +0.21%, and June Nasdaq 100 E-Mini futures (NQM2 3) are up +0.37%. U.S. stock index futures this morning are moderately higher after U.S. Mar producer prices rose less than expected, easing inflation concerns. Also, weekly jobless claims rose...

Barchart · Apr 13, 2023